Life Healthcare Group Holdings Earnings Call Transcripts
Fiscal Year 2025
-
Operational and financial performance was strong, with 6% revenue growth, robust cash generation, and significant dividends. Asset optimization and integration of acquisitions remain key focus areas, with margin improvement and cost savings targeted for the coming years.
-
Revenue grew 8.1% and normalized EPS rose 9.1% year-over-year, with strong cash flow and a 10.5% higher interim dividend. Strategic expansions and asset optimization continue, while the LMI transaction is set to deliver significant shareholder returns.
Fiscal Year 2024
-
Group revenue rose 12.7% year-over-year, driven by strong growth in Life Molecular Imaging and solid performance in Southern Africa. ZAR 10.6 billion was returned to shareholders, and a robust balance sheet supports ongoing expansion and efficiency initiatives.